Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic that encompasses three distinct clinical phenotypes: uncomplicated fatty liver, non-alcoholic steato-hepatitis (NASH) and NASH-related cirrhosis with its complications, including hepatocellular carcinoma. To date, no pharmacological treatments have been approved and lifestyle...
-
2022 (v1)PublicationUploaded on: April 14, 2023
-
2020 (v1)Publication
In patients with HCV-related advanced cirrhosis, the effects of SVR by DAAs on decompensation and liver deaths is less clearcut, since up to 30 % of patients do not improve, and no predictors of outcome have been identified. We used 13 C-aminopyrine breath test (ABT) to assess whether its changes can predict liver-related outcomes after DAA...
Uploaded on: April 14, 2023 -
July 11, 2023 (v1)Publication
Nonalcoholic fatty liver disease (NAFLD) is a clinical condition that encompasses various forms of liver damage not caused by chronic alcohol consumption. In the absence of other etiologies, it ranges from steatosis to nonalcoholic steatohepatitis and cirrhosis. The prevalence of NAFLD has considerably increased over the last years owing to the...
Uploaded on: July 13, 2023 -
2017 (v1)Publication
Determining risk for recurrence or survival after curative resection or ablation in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) is important for stratifying patients according to expected outcomes in future studies of adjuvant therapy in the era of direct-acting antivirals (DAAs). The aims of this meta-analysis...
Uploaded on: April 14, 2023 -
October 26, 2022 (v1)Publication
Fibroblast growth factor 21 (FGF21) is a liver-derived hormone with pleiotropic beneficial effects on metabolism. Paradoxically, FGF21 levels are elevated in metabolic diseases. Interventions that restore metabolic homeostasis reduce FGF21. Whether abnormalities in FGF21 secretion or resistance in peripheral tissues is the initiating factor in...
Uploaded on: December 4, 2022 -
2018 (v1)Publication
Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few...
Uploaded on: April 14, 2023 -
2020 (v1)Publication
Wilson's disease (WD) is a rare genetic disorder with protean manifestations. Even if liver transplantation (LT) could represent an effective therapeutic option for patients with end-stage liver disease, it has remained controversial in presence of neuropsychiatric involvement. This study aimed to examine the frequency of adult LT for WD in...
Uploaded on: April 14, 2023 -
2017 (v1)Publication
A major problem in assessing the long-term outcome of HCV-infected cirrhotic patients with successfully treated Barcelona Clinic Liver Cancer (BCLC) A hepatocellular carcinoma (HCC) arises from the lack of models accounting for early changes during follow-up.
Uploaded on: April 14, 2023 -
2017 (v1)Publication
Few data are available on the virological and clinical outcomes of advanced liver disease patients retreated after first-line DAA failure.
Uploaded on: April 14, 2023